SYRS News and Press, Syros Pharmaceuticals Inc. From 02/28/22

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual inv...

Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...

The U.S. Food and Drug Administration granted orphan drug designation to Syros Pharmaceuticals' (NASDAQ:SYRS) tamibarotene to treat myelodysplastic syndrome (MDS). Tamibarotene is currently being evaluated in combination with azacitidine in a phase 3 trial, dubbed SELECT-MDS-1, to treat&...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (M...

Initiated Expansion Cohort of SY-5609 with Chemotherapy in Pancreatic Cancer Patients Expects to Report Data from Three Clinical Trials Across Hematology and Selective CDK Inhibitor Programs in 2022 Now Expects to Initiate Phase 1 Single Agent Trial of SY-5609 in Hemat...

Tamibarotene Phase 2 AML data is expected in 2022. Positive trial AML or MDS data would lead to an application to the FDA in 2024. Expanded trials for SY-5609 are getting underway. For further details see: Syros Pharmaceuticals Is A Buy As New Trials Start

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will al...

Syros Pharmaceuticals, Inc. (SYRS) Q3 2021 Earnings Conference Call November 5, 2021 8:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications Nancy Simonian - President and Chief Executive Officer Jason Haas - Chief Financial Officer David Roth - Chief Medical Offi...

First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Study of SY-2101 in APL Presented Phase 1 Data of SY-5609 at ESMO, Demonstrating Clinical Activity at Tolerable Doses and Supporting Development in Three Combination Regimens Expande...

AMCX,AMR,AXL,BBU,BEP,CGAU,CGC,CLMT,CNK,CNTY,D,DKNG,DOC,DTM,EAF,ELAN,ENB,EOG,ERJ,ESNT,FLR,GCI,OTCPK:GCTAF,GECC,GLP,GOOS,GRPN,GT,HE,HMC,INTT,JCI,KIM,LMRK,MFA,MGA,MITT,NMRK,NOG,NWN,OFS,ONCY,PLYM,PNW,REV,SII,SRE,SSP,SYRS,TEN,TRP,TU,TUSK,VRS,VST,VTR,XELA For Seeking Alpha's full earnings season ca...